Protara Therapeutics Inc. (TARA)
NASDAQ: TARA
· Real-Time Price · USD
3.44
-0.06 (-1.71%)
At close: May 01, 2025, 3:59 PM
3.48
1.02%
Pre-market: May 02, 2025, 08:55 AM EDT
Company Description
Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the identifying and advancing transformative therapies for the treatment of cancer and rare diseases.
The company's lead program is TARA-002, an investigational cell therapy for the treatment of lymphatic malformations.
It also develops intravenous choline chloride, an investigational phospholipid substrate replacement therapy for the treatment of intestinal failure associated liver disease.
The company was formerly known as ArTara Therapeutics, Inc. and changed its name to Protara Therapeutics, Inc. in May 2020.
Protara Therapeutics, Inc. is headquartered in New York, New York.
Protara Therapeutics Inc.
| Country | United States |
| IPO Date | Oct 22, 2014 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 28 |
| CEO | Jesse Shefferman |
Contact Details
Address: 345 Park Avenue South New York, New York United States | |
| Website | https://www.protaratx.com |
Stock Details
| Ticker Symbol | TARA |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001359931 |
| CUSIP Number | 74365U107 |
| ISIN Number | US74365U1079 |
| Employer ID | 20-4580525 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Jesse Shefferman | Co-founder, Chief Executive Officer, President & Director |
| Patrick Fabbio M.B.A. | Chief Financial Officer |
| Hannah Fry | Vice President, Principal Accounting Officer & Controller |
| Justine O'Malley | Senior Vice President of Investor Relations & Corporate Affairs |
| Mary J. Grendell J.D. | General Counsel & Corporate Secretary |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 28, 2025 | SCHEDULE 13G/A | [Amend] Filing |
| Apr 28, 2025 | 424B7 | Filing |
| Apr 28, 2025 | 8-K | Current Report |
| Apr 25, 2025 | DEFA14A | Filing |
| Apr 25, 2025 | ARS | Filing |
| Apr 25, 2025 | DEF 14A | Filing |
| Apr 17, 2025 | 4 | Filing |
| Apr 17, 2025 | 3 | Filing |
| Mar 28, 2025 | 4 | Filing |
| Mar 28, 2025 | 4/A | [Amend] Filing |